Original from: 360dx

South Korean diagnostic firm Noul said Wednesday that it has inked an agreement to launch its hematology and malaria testing tools in Europe through German lab chain Limbach Group.

The agreement involves the implementation in Limbach Group labs of Noul's MiLab testing system including its MiLab BCM hematology test and MiLab MAL malaria test. MiLab is an automated instrument that uses microscopy and artificial intelligence-developed algorithms to analyze samples.

Financial and other terms of the agreement were not disclosed. Noul CEO David Lim said in a statement that the deal with Limbach Group is the company's first contract with a major lab chain in Europe.

"Noul plans to extend the reach into the European market with all of its test portfolios, beginning with the well-referenced MiLab MAL and BCM, and in the near future with the cervical cancer solution recognized by WHO-UNITAID," he said.

The company noted that the Limbach Group is Germany's largest clinical lab network.

Source: Noul, Limbach Group Ink Deal for Hematology, Malaria Testing in Europe